Insufficient liquidity / going concern
Management says current cash is not enough to fund corporate overhead for 12 months.
- Scope
- Corporate overhead, debt service, and operating continuity
- Materiality
- high
Foxo Technologies Inc.
FOXO Technologies Inc. is a U.S.-based healthcare and life-sciences company built around two operating areas: healthcare services and Labs/Life research and testing activities. Its business combines acquired healthcare operations with epigenetic biomarker research, bioinformatics services, and royalty/commission-based revenue streams tied to longevity and life-insurance-related activities.
−59,5 %
−75,9 %
+304,0 %
0.11
0.10
| % | |
|---|---|
| Healthcare Services | 95% Hospital, ancillary, and substance use disorder treatment services delivered through acquired operations. |
| Labs and Life Services | 5% Epigenetic testing, bioinformatics services, royalties, and life-insurance-related commissions. |
The company serves healthcare patients and payers through its acquired healthcare operations, with revenue driven by...
- Healthcare patients and payersprimary
Patients receive hospital and treatment services, while insurers and government programs reimburse a large share of the revenue.
- Research organizationssecondary
Buy epigenetic testing and bioinformatics services for data analysis and biomarker-related research.
- Royalty and commission counterpartiessecondary
Generate small revenue streams from biomarker-related royalties and life insurance policy commissions.
- Consumer wellness usersemerging
Potential users of the AI epigenetic app being developed under the KR8 agreement.
FOXO’s disclosed operating territory for the KR8 license is limited to the U.S., Canada, and Mexico, indicating a North...
- •U.S. is the core operating market for healthcare revenue
- •KR8 license territory covers the U.S., Canada, and Mexico
- •North American scope matters for app commercialization rights
- •Revenue depends on U.S. payer and patient collection dynamics
- •No country-level revenue disclosure was provided in the excerpts
Management is focused on keeping the business funded while scaling acquired healthcare operations and extracting cash...
01
Stabilize liquidity and fund operationsshort-term
The company says current cash is insufficient to fund overhead without new financing.
02
Integrate and monetize acquired healthcare assetsshort-term
Myrtle and RCHI/SCCH are expected to produce a small cash flow surplus through 2025.
03
Build Labs bioinformatics into a primary offeringmedium-term
Bioinformatics services can broaden the company beyond healthcare reimbursement economics.
04
Commercialize epigenetic consumer and research applicationsmedium-term
The KR8 license and epigenetic testing services could create higher-value recurring revenue.
FOXO faces substantial going-concern and financing risk because management states it cannot fund operations for at...
Payer reimbursement and collection risk
Healthcare revenue is recorded net of contractual allowances and implicit price concessions.
- Scope
- Healthcare segment revenue and receivables
- Materiality
- high
Acquisition integration risk
Recent acquisitions must be integrated and turned into positive cash flow.
- Scope
- Myrtle, RCHI/SCCH operations
- Materiality
- medium
Dilution and capital structure risk
Funding may require equity issuance, convertible debt, or non-cash settlements.
- Scope
- Existing shareholders
- Materiality
- high
Revenue recognition under Topic 606
Reported revenue and accounts receivable
Allowance and collectability estimates
Revenue, receivables, and bad debt-related adjustments
Going-concern assessment
Balance sheet and disclosure risk
Acquisition-related valuation judgments
Assets, liabilities, and future impairment risk
Foxx Development Holdings Inc.
FOXX · Computer Communications Equipment
EXICURE, INC.
XCUR · Pharmaceutical Preparations
MYRIAD GENETICS INC
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
MAXIMUS, INC.
MMS · Services-Business Services, NEC
MAXIMUS is a U.S.-based government services contractor that designs and operates tech-enabled programs for federal, state, local, and international public agencies.
Phio Pharmaceuticals Corp.
PHIO · Pharmaceutical Preparations
Korro Bio, Inc.
KRRO · Pharmaceutical Preparations
: 28/04/2026